Patent Number: 8,718,996

Title: Method for predicting whether a cancer patient will not benefit from platinum-based chemotherapy agents

Abstract: A testing method for identification whether a cancer patient is a member of a group or class of cancer patients that are not likely to benefit from administration of a platinum-based chemotherapy agent, e.g., cisplatin, carboplatin or analogs thereof, either alone or in combination with other non-platinum chemotherapy agents, e.g., gemcitabine and paclitaxel. This identification can be made in advance of treatment. The method uses a mass spectrometer obtaining a mass spectrum of a blood-based sample from the patient, and a computer operating as a classifier and using a stored training set comprising class-labeled spectra from other cancer patients.

Inventors: Roder; Joanna (Steamboat Springs, CO), Roder; Heinrich (Steamboat Springs, CO), Grigorieva; Julia (Steamboat Springs, CO)

Assignee: Biodesix, Inc.

International Classification: G01N 33/48 (20060101); G06G 7/48 (20060101); G06G 7/58 (20060101); G01N 33/50 (20060101)

Expiration Date: 5/06/12018